Infusion Therapy Insurance Denied: How to Appeal

Infusion therapy — intravenous medications administered over an extended period — is used to treat conditions ranging from infections and autoimmune diseases to cancer and immune deficiencies. When your insurer denies infusion therapy or attempts to redirect you from home infusion to an outpatient infusion center, you have clear grounds for appeal.

Two Types of Infusion Denials

Type 1: The therapy itself is denied as not medically necessary or experimental. This involves standard medical necessity appeal arguments.

Type 2: The site of care is denied — the insurer approves the infusion therapy but requires it to be done in an outpatient infusion center rather than at home, arguing that home infusion is not medically necessary. This "site of care" denial is increasingly common as insurers push patients toward lower-cost outpatient settings.

This guide addresses both, with particular attention to site-of-care denials, which are legally and clinically contestable.

Site-of-Care Denials: The Core Issue

Home infusion therapy is generally more expensive for insurers in the short term than outpatient infusion centers. Insurers respond by requiring patients to use outpatient centers, even when home infusion is clinically appropriate or preferred.

However, the site-of-care determination must be based on clinical appropriateness — not purely cost. Insurers cannot deny home infusion coverage solely because an outpatient center is cheaper if the physician documents clinical reasons why home infusion is medically necessary.

Clinical reasons supporting home infusion over outpatient:

• Physical inability to travel: The patient has a mobility limitation, serious fatigue, or weakness that makes regular travel to an infusion center medically inappropriate
• Infection risk: Immunocompromised patients face heightened risk of pathogen exposure in outpatient infusion centers
• Monitoring needs that can be managed at home: A trained home infusion nurse can monitor the patient effectively in their own environment
• Geographic access: The patient lives far from an infusion center, making regular attendance impractical or impossible
• Therapy duration: Very long infusions (8–12 hours or more) are often more appropriately done at home than in an outpatient center
• Pediatric patients: Home infusion reduces disruption to schooling and family life and may be clinically preferred

How to Appeal a Site-of-Care Denial

Step 1: Obtain the denial letter and the insurer's clinical criteria for home infusion. Request the specific policy document.

Step 2: Have your physician document the clinical rationale for home infusion. The letter should specifically address:

• Your current functional status and ability to travel
• Any clinical risk factors for outpatient infusion (immunosuppression, infection risk)
• The specific drug being infused and why home administration is appropriate
• The home infusion provider's qualifications and monitoring protocols

Step 3: Contact the National Home Infusion Association (NHIA). The NHIA (nhia.org) publishes resources for patients and providers dealing with site-of-care denials and has model appeal language.

Step 4: Write the internal appeal. Argue that the denial of home infusion:

• Is not supported by clinical evidence in your specific case
• Overrides your physician's clinical judgment without adequate clinical justification
• May constitute an unreasonable restriction under your plan

Step 5: Escalate to External Independent Review: Complete Guide" class="auto-link">external review. An external reviewer applying clinical standards will evaluate whether home infusion is medically appropriate for your specific situation — and frequently agrees with the treating physician.

Therapy Itself Denied as Not Medically Necessary

If the infusion therapy itself (not just the site) is denied:

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization issues: Many infusion drugs require prior auth. Ensure your prescribing physician submitted all required documentation — diagnosis codes, specialty documentation, prior treatment history.

Biologic infusions (e.g., Remicade, Ocrevus, Rituxan): These frequently require:

• Documented diagnosis (Crohn's disease, MS, RA, etc.)
• Failure of first-line treatments (methotrexate, other DMARDs)
• Physician specialty documentation (gastroenterologist, neurologist, rheumatologist)

IVIG (intravenous immunoglobulin): IVIG is denied frequently due to narrow coverage criteria. Approved indications include primary immunodeficiency, CIDP, ITP, and certain autoimmune conditions. Off-label use requires strong physician documentation and peer-reviewed literature support.

Documentation Checklist for Infusion Appeals

• Physician letter of medical necessity (specific to the denied therapy and/or site of care)
• Relevant diagnostic records (labs, imaging, specialist notes)
• Treatment history showing prior therapy attempts if step therapy is required
• Home infusion provider credentials and monitoring protocol (for site-of-care appeals)
• Clinical guidelines from relevant specialty societies (ACR, AAN, CCFA, etc.)
• Any peer-reviewed literature supporting the specific drug and indication

Medicare and Infusion Coverage

Medicare covers infusion drugs under Part B when administered by a physician or in an outpatient setting. Home infusion drugs are covered under the Medicare Part D drug benefit — the coverage, access, and cost-sharing structure differs significantly. Medicare added a home infusion therapy services benefit in 2021, which covers the professional services of a home infusion pharmacy.

For Medicare denials, file a Redetermination with your Medicare Administrative Contractor.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal